Remove

PTO/SB/08a (08-03 )
Approved for use through 97/31/2006, OMS 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

	Application Number		
	Filing Date		2006-05-25
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Michael BERTHON-JONES et		ael BERTHON-JONES et al
( Not for submission under 37 CFR 1.99)	Art Unit		
(Not for Submission under or of it ison)	Examiner Name		
	Attorney Docket Number		3869/029 US

U.S.PATENTS

U.S.PATENTS			NETIOVE						
		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6532957		2003-03-18	BERTHON-J	ONES et all			
	2	6739336		2004-05-25	JALDE et al				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1								
If you wis	h to a	dd additional U.S. Publ	ished Ac	polication citatio	n information	please click the Ad-	d button	Add	
				FOREIGN PA	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lir where Relevant Passages or Relevant Figures Appear	7.
	1	01/19440	wo		2001-03-22	RESMED LTD.			
	2	1 086 716	EP		2001-03-28	SIEMENS-ELEMA	AB		

	Application Number			
INFORMATION DIGGI COURT	Filing Date		2006-05-25	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mich		ael BERTHON-JONES et al	
(Not for submission under 37 CFR 1.99)	Art Unit			
(,	Examiner Name			
	Attorney Docket Number		3869/029 US	

	3	1 346 743	EP		2003-09-24	WEINMANN MED		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where publisher.								Τs
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered							
*EXAMIN	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

See Kind Codes of USPTO Patient Documents at <a href="https://www.USPTO.CDV">www.LSPTO.CDV</a> or NMPEP 691.04. Father office that assaud the document, by the two-letter code (WIPO Standard ST 13). For Japanese patent documents, the relication of the year of the single of the Emperor must precide the sent in unber of the patent document. The patent should be a reclaim of the forecomment of the WIPO Standard ST 1/4 postale. Applicant is to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the Patent ST to place a code can the New Test of the New Test

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date 2006-05-25 Filing Date 12006-05-25 Filing Date 12006-05-25 First Number Number Number 12006-05-25 First Number Number

## CERTIFICATION STATEMENT

Please see 3/	CFR 1.97 and	1.98 to make the	appropnate selection	(S):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Michael I. Rackman/	Date (YYYY-MM-DD)	2006-05-25
Name/Print	Michael I. Rackman	Registration Number	20639

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.